180 related articles for article (PubMed ID: 26366474)
1. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
2. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
[TBL] [Abstract][Full Text] [Related]
4. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
[TBL] [Abstract][Full Text] [Related]
6. BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma.
Sako A; Matsuse M; Saenko V; Tanaka A; Otsubo R; Morita M; Kuba S; Nishihara E; Suzuki K; Ogi T; Kawakami A; Mitsutake N
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38576411
[TBL] [Abstract][Full Text] [Related]
8. Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition.
Barsouk A; Elghawy O; Stone S; Singh A
Anticancer Drugs; 2024 Apr; ():. PubMed ID: 38696710
[TBL] [Abstract][Full Text] [Related]
9. Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
Toda S; Hiroshima Y; Iwasaki H; Masudo K
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38630010
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay.
Picarsic JL; Buryk MA; Ozolek J; Ranganathan S; Monaco SE; Simons JP; Witchel SF; Gurtunca N; Joyce J; Zhong S; Nikiforova MN; Nikiforov YE
Pediatr Dev Pathol; 2016; 19(2):115-22. PubMed ID: 26367451
[TBL] [Abstract][Full Text] [Related]
11. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
12. Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.
Gertz RJ; Nikiforov Y; Rehrauer W; McDaniel L; Lloyd RV
Arch Pathol Lab Med; 2016 Feb; 140(2):134-9. PubMed ID: 26910217
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
15. Multimodality Treatment of Pediatric Esthesioneuroblastoma.
Venkatramani R; Pan H; Furman WL; Marron JM; Haduong J; Friedrich-Medina P; Mahajan A; Bavle A; Wu H; Chintagumpala M
Pediatr Blood Cancer; 2016 Mar; 63(3):465-70. PubMed ID: 26514449
[TBL] [Abstract][Full Text] [Related]
16. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
[TBL] [Abstract][Full Text] [Related]
17. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
18. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
19. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
Mostoufi-Moab S; Labourier E; Sullivan L; LiVolsi V; Li Y; Xiao R; Beaudenon-Huibregtse S; Kazahaya K; Adzick NS; Baloch Z; Bauer AJ
Thyroid; 2018 Jan; 28(1):60-67. PubMed ID: 29108474
[TBL] [Abstract][Full Text] [Related]
20. Molecular Genetics of Thyroid Cancer in Children and Adolescents.
Bauer AJ
Endocrinol Metab Clin North Am; 2017 Jun; 46(2):389-403. PubMed ID: 28476228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
